Life Science Investing ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Life Science Investing Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Life Science Investing FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
RZOLV Technologies Successfully Completes Bulk-Scale Vat Leach Test at Operating Gold Mine, Advancing Commercial Validation of RZOLV Non-Cyanide Gold Extraction
TERRA CLEAN PROVIDES CORPORATE UPDATE AND WELCOMES THE UNITED STATES DEPARTMENT OF ENERGY'S RECENT NEW DOMESTIC NUCLEAR FUEL SUPPLY CHAIN & URANIUM FOCUS
SAGA Metals Reports Strongest Critical Mineral Drill Results To-Date at Radar Ti-V-Fe Project in Labrador
